Objectives: Recently, there has been a decrease in the eradication rate of Helicobacter pylori due to the increase in antibiotic resistance of this bacterium. Plaunotol, a cytoprotective anti-ulcer agent, exhibits antibacterial activity against H. pylori. The purpose of the present study was to investigate the effect of plaunotol in combination with clarithromycin against clarithromycin-resistant H. pylori clinical isolates.
Introduction
Helicobacter pylori is a Gram-negative bacterium associated with peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer. The discovery of H. pylori has already changed the prognosis of peptic ulcer disease, with most patients being cured at their first presentation. 1, 2 Eradication of H. pylori is very important to prevent relapse and accelerate the healing of peptic ulcer disease, 3 and only tripledrug therapy [ proton pump inhibitor (PPI) þ amoxicillin þ clarithromycin] is currently permitted in Japan. Triple-drug therapy has a strong antibacterial effect against H. pylori and has a high eradication rate. 4 However, the eradication rate of H. pylori using triple-drug therapy has decreased 5, 6 due to the increase in clarithromycin-resistant strains of H. pylori. 7, 8 Plaunotol, a cytoprotective anti-ulcer agent, enhances the antibacterial activity of clarithromycin; 9,10 however, it is unclear whether plaunotol enhances the antibacterial activity of clarithromycin against clarithromycin-resistant H. pylori. Plaunotol shows antibacterial activity against H. pylori and plaunotol in combination with clarithromycin exhibits synergistic or additive activity against clarithromycin-susceptible H. pylori in vitro and in vivo. Triple-drug therapy is instituted before the detection of clarithromycin-resistant H. pylori. Therefore, it is useful to evaluate the combined effect of plaunotol with clarithromycin against clarithromycin-resistant H. pylori. In this study, we evaluated the antibacterial activity of plaunotol in combination with clarithromycin against clarithromycin-resistant H. pylori isolates by using the agar dilution chequerboard method. The in vivo activity of the plaunotol/clarithromycin combination was also examined in a gastritis model in Mongolian gerbils infected with a clinical isolate of clarithromycin-resistant H. pylori.
Materials and methods

Antibacterial agents
Plaunotol (Daiichi Sankyo Co., Ltd, Tokyo, Japan) and clarithromycin (Taisho Pharmaceutical Co., Ltd, Tokyo, Japan) were used.
Microorganisms
Twenty-one H. pylori clinical isolates used in this study were isolated from gastric biopsy samples obtained during a routine endoscopy. The gastric biopsy material was processed according to the standard methodology, and H. pylori was identified based on colony morphology, Gram staining and catalase-, oxidase-and urease-positive reactions. Twenty-one clarithromycin-resistant strains (MIC ! 1 mg/L) were maintained at 2808C in Brucella broth with 25% glycerol until usage. Stock culture was grown in Brucella broth (Nippon Becton Dickinson Co. Ltd) containing 3% heat-inactivated fetal bovine serum (FBS) and antibiotics (2.5 mg/L amphotericin B, 5 mg/L vancomycin, 2.5 mg/L trimethoprim and 125 IU/L polymyxin B) under microaerobic conditions with gas generator envelopes (AnaeroPack, Mitsubishi Gas Chemical Co., Inc.) in gas jars at 378C for 4 days.
Animals
A total of 36 specific-pathogen-free, 5-week-old male Mongolian gerbils (MGS/Sea, Kyudo Co., Ltd) were housed in plastic cages on hardwood chip bedding in an air-conditioned biohazard room with a 12:12 h light:dark cycle. The experimental design was approved by the Animal Care Committee of the Nagoya City University Animal Research Institute and the animals were cared for in accordance with institutional guidelines, which comply with the instructions of the Health, Labour and Welfare Ministry concerning animal experiments.
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Stock clarithromycin-resistant H. pylori culture was grown in Brucella broth containing 3% FBS under microaerobic conditions. After 1 day of fasting, 6-week-old Mongolian gerbils were orally inoculated with 2 mL of bacterial suspension having a density of 1 Â 10 8 cfu/mL. Uninfected gerbils were mock-inoculated with sterile Brucella broth containing 3% FBS.
Determination of MIC
Stock cultures of bacteria were grown on brain heart infusion agar (BHIA; Difco Laboratories) supplemented with 5% defibrinated horse blood (Nippon Bio-Supply) at 378C for 3 days in gas jars with CampyPack. The MICs were measured on BHIA supplemented with 5% defibrinated horse blood by using the 2-fold dilution method. Plaunotol and clarithromycin were dissolved in DMSO and methanol, respectively. Inocula were prepared by suspending the bacterial growth on BHIA supplemented with 5% defibrinated horse blood plates in physiological saline to achieve a density equivalent to that of a 2.0 McFarland standard. A final inoculum of 10 4 -10 5 cfu/spot was employed using an Auto-Inoculator (Dai Nippon Seiki Co., Ltd, Kyoto, Japan). All the plates were incubated for 3 days at 358C under microaerobic conditions. The MIC was defined as the lowest concentration of the drug that prevented visible growth after 3 days of incubation.
Determination of in vitro interaction
Antimicrobial interactions between plaunotol and clarithromycin against 15 clinical isolates were evaluated by the chequerboard titration method. The inoculum, media and culture conditions for this evaluation were the same as those described for the MIC determination.
The fractional inhibitory concentrations (FICs) were calculated as follows:
The FIC indices were interpreted as follows: 0.5, synergy; .0.5-1, additive; .1-4.0, indifference; .4, antagonism.
Determination of in vivo interaction
The experimental design is illustrated in Figure 1 . Thirty-six gerbils were grouped into five groups. H. pylori was inoculated into four (Groups A, B, C and D) of five groups at experimental week 1. The remaining group (Group E) received Brucella broth containing 3% FBS. Plaunotol and clarithromycin were dissolved in 0.5% sodium carboxymethyl cellulose (CMC solution, Kanto Chemical Co., Inc. Groups D and E received oral CMC. The gerbils were sacrificed humanely at 12 weeks. All gerbils were deeply anaesthetized with ether, laparotomized and exsanguinated from the inferior vena cava, followed by excision of their stomachs. Each glandular stomach was fixed in 10% formalin neutral buffer solution, deodorized (Wako Pure Chemical Industries, Ltd) and routinely processed for histopathological examination.
Histopathological analyses
Tissue sections were immunohistochemically stained for examination of H. pylori (anti-H. pylori serum, Dako, Copenhagen). The degree of H. pylori density was graded according to the criteria modified from the Updated Sydney System 12 by scoring the following parameters: mononuclear cell infiltration (0-3: 0, normal; 1, mild infiltration into lamina propria; 2, moderate infiltration into lamina propria; 3, marked infiltration into lamina propria and multiple lymphoid follicle formation); neutrophil infiltration (0-3: 0, none; 1, number of neutrophils in the pyloric mucosa in a line from the forestomach to the duodenum ,50/mm; 2, 50 -100/mm; 3, .100/mm); and H. pylori density (0 -3: 0, none; 1, mild H. pylori density; 2, moderate; 3, marked). 13 Two independent individuals (M. S. and T. Mizoshita) were blind with regard to information concerning H. pylori infection and treatment, and judged the histology.
Statistical analysis
The Mann-Whitney U-test was used to establish the significance of differences in microscopic H. pylori density. P values of ,0.05 were considered to be statistically significant.
Results and discussion
Regarding the genetic diversity of clarithromycin-resistant H. pylori, Masaoka et al.
14 have demonstrated that dilution agar methods should be combined with PCR-restriction fragment length polymorphism (PCR-RFLP) analysis before secondline eradication to increase the accuracy of clarithromycin susceptibility testing and to improve eradication efficacy. In this study, we demonstrated the effect of plaunotol in combination with clarithromycin against clarithromycin-resistant H. pylori. Table 1 (Table 2) . Thus, by using the chequerboard titration method, we demonstrated that plaunotol synergistically enhanced the antibacterial activity of clarithromycin against clarithromycin-resistant H. pylori in vitro. This tendency is in accordance with a previous report of clarithromycinsusceptible H. pylori from Koga et al. 10 As plaunotol is suggested to cause a change in fluidity with the associated increased membrane permeability, 15 plaunotol might potentiate the anti-H. pylori activity of clarithromycin by increasing the permeability of the membranes of even clarithromycin-resistant H. pylori. Table 3 shows the therapeutic effects of plaunotol in combination with clarithromycin. The H. pylori infection scores of Groups B and C were lower than that of Group D; however, the difference was not significant. In contrast, the H. pylori infection score of Group A receiving the combination therapy was significantly lower than that of Group D; this indicated the synergistic/ additive effect of the plaunotol/clarithromycin combination. However, acute inflammation scores and chronic inflammation scores based upon the Updated Sydney System were not significantly different. Fukuda et al. 16 have reported that the combination of plaunotol, clarithromycin and a PPI showed a 69% eradication rate as compared with a 38% eradication rate achieved with a combination of clarithromycin and a PPI. Thus far, there has been no study on the synergistic effect of plaunotol in combination with clarithromycin against clarithromycinresistant H. pylori strains. Our study is the first to demonstrate 
Conclusions
We demonstrated that plaunotol, a cytoprotective anti-ulcer agent, in combination with clarithromycin exhibits a synergistic effect on clarithromycin-resistant H. pylori strains in vitro and in vivo. These results suggest that plaunotol could play a useful role in combination with clarithromycin in the treatment of diseases associated with clarithromycin-resistant H. pylori.
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